.png)
Agenzia Italiana del Farmaco
Direct communication with healthcare professionals on INSUMAN RAPID (insulin human): temporary supply shortage and marketing cessation - Direct communication with healthcare professionals on INSUMAN RAPID (insulin human): temporary supply shortage and marketing cessation
Direct communication with healthcare professionals on INSUMAN RAPID (insulin human): temporary supply shortage and marketing cessation
Issues at a manufacturing site in the past months resulted in a temporary critical global supply situation affecting the product Insuman Rapid.
In Italy the shortage is expected to begin on:
- - 31/01/2023 for INSUMAN RAPID A.I.C. n. 038923431
- - 23/01/2023 for INSUMAN RAPID A.I.C. n. 034185850
The expected date to return to normal supply is December 2023.
No new patients should be initiated with any of the impacted INSUMAN RAPID presentations and existing patients should be switched to suitable alternatives. Interruption of insulin treatment is potentially life threatening.
Therefore, replacement with alternative insulin formulations is needed to avoid hyperglycaemia and serious complications.
Published on: 16 January 2023
